Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Naftopidil (KT-611) 是一种选择性的 alpha1-肾上腺素受体 (α1-adrenoceptor) 拮抗剂,对克隆的人类 α1a、α1b 和 α1d 亚型肾上腺素受体的亲和力Ki 分别为 3.7 nM、20 nM 、1.2 nM。它具有抗增殖活性,可用于研究前列腺增生。 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 Naftopidil dihydrochloride 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
500 mg | ¥ 326 | 待询 | ||
1 g | ¥ 528 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 395 | 现货 |
产品描述 | Naftopidil (KT-611) (INN, marketed under the brand name Flivas), an antihypertensive medicine, is used as a selective α1-adrenergic receptor antagonist or α-blocker. |
靶点活性 | α1B-adrenergic receptor:20 nM(Ki), α1A-adrenergic receptor:3.7 nM(Ki), α1D-adrenergic receptor:1.2 nM(Ki) |
体外活性 | Naftopidil is selective for the alpha1d-adrenoceptor with approximately 3- and 17-fold higher affinity than for the alpha1a- and alpha1b-adrenoceptor subtypes, respectively. [1] Naftopidil has growth inhibitory effect in androgen-sensitive and -insensitive human prostate cancer cell lines. Naftopidil induces p21(cip1) but not p27(kip1) in PC-3 cells. [2] Naftopidil induces apoptosis in all the investigated malignant mesothelioma cells, and a similar effect is obtained with prazosin, another α1-adrenoceptor blocker. Naftopidil-induced reduction in cell viability is inhibited by GF109203X, while prazosin-induced in cell viability is less affected. [3] Naftopidil, an alpha 1-adrenoreceptor antagonist produces a concentration-dependent inhibition ofcollagen-induced Ca2+ mobilization, maximum inhibition (22.9%) occurring with 40 mM Naftopidil. Naftopidil also inhibits the adrenaline-induced rise in [Ca2+]i in a concentration-dependent manner (30 mM doxazosin), significant inhibitions of platelet aggregation also being produced. [4] Naftopidil (0.3, 1, and 3 μM) inhibits 5-HT-induced bladder contraction in a concentration-dependent manner. Naftopidil inhibits both the 5-HT(2A) and 5-HT(2) receptor agonists-induced bladder contractions. Naftopidil binds to the human 5-HT(2A) and 5-HT(2B) receptors with pKi values of 6.55 and 7.82, respectively. [5] |
体内活性 | Naftopidil selectively inhibits the phenylephrine-induced increase in prostatic pressure compared with mean blood pressure in the anesthetized dog model. [1] Naftopidil inhibits 5-HT-induced bladder contraction via blockade of the 5-HT(2A) and 5-HT(2B) receptors in rats. [5] |
别名 | KT-611, 萘哌地尔, BM-15275 |
分子量 | 392.49 |
分子式 | C24H28N2O3 |
CAS No. | 57149-07-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 73 mg/mL (186 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5478 mL | 12.7392 mL | 25.4784 mL | 63.6959 mL |
5 mM | 0.5096 mL | 2.5478 mL | 5.0957 mL | 12.7392 mL | |
10 mM | 0.2548 mL | 1.2739 mL | 2.5478 mL | 6.3696 mL | |
20 mM | 0.1274 mL | 0.637 mL | 1.2739 mL | 3.1848 mL | |
50 mM | 0.051 mL | 0.2548 mL | 0.5096 mL | 1.2739 mL | |
100 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.637 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Naftopidil 57149-07-2 GPCR/G Protein Neuroscience Adrenergic Receptor hyperplasia BM 15275 KT-611 inhibit prostate pressure BM15275 KT 611 萘哌地尔 canine Inhibitor BM-15275 KT611 Beta Receptor prostatic inhibitor